Top

Published in:

09-06-2024 | Human Immunodeficiency Virus | Original Paper

Correlates of Adherence to Oral and Vaginal Pre-exposure Prophylaxis (PrEP) Among Adolescent Girls and Young Women (AGYW) Participating in the MTN-034/REACH Trial

Authors: Kenneth Ngure, Erica N. Browne, Krishnaveni Reddy, Barbara A. Friedland, Ariane van der Straten, Thesla Palanee-Phillips, Rita Nakalega, Brenda Gati, Hadijah N. Kalule, Bekezela Siziba, Lydia Soto-Torres, Gonasagrie Nair, Morgan Garcia, Connie Celum, Sarah T. Roberts

Published in: AIDS and Behavior | Issue 9/2024

Abstract

We evaluated correlates of adherence to PrEP, including daily oral tenofovir disoproxil fumarate in combination emtricitabine (oral FTC/TDF) and the monthly dapivirine ring (ring)among adolescent girls and young women (AGYW) in the MTN-034/REACH study. We enrolled 247 AGYW aged 16–21 years in South Africa, Uganda and Zimbabwe (ClinicalTrials.gov: NCT03074786). Participants were randomized to the order of oral FTC/TDF or ring use for 6 months each in a crossover period, followed by a 6-month choice period. We assessed potential adherence correlates—individual, interpersonal, community, study, and product-related factors—quarterly via self-report. We measured biomarkers of adherence monthly; high adherence was defined as > 4 mg dapivirine released from returned rings or intracellular tenofovir diphosphate levels ≥ 700 fmol/punch from dried blood spots (DBS). We tested associations between correlates and objective measures of high adherence using generalized estimating equations. High adherence to oral FTC/TDF was significantly associated with having an older primary partner (p = 0.04), not having exchanged sex in the past 3 months (p = 0.02), and rating oral FTC/TDF as highly acceptable (p = 0.003). High ring adherence was significantly associated with unstable housing (p = 0.01), disclosing ring use to a male family member (p = 0.01), and noting a social benefit from study participation (p = 0.03). All associations were moderate, corresponding to about 6%–10% difference in the proportion with high adherence. In our multinational study, correlates of adherence among African AGYW differed for oral FTC/TDF and the ring, highlighting the benefit of offering multiple PrEP options.

Available only for authorised users

“UNAIDS 2021. Global HIV & AIDS statistics — Fact sheet.” [Online]. Available: https://www.unaids.org/en/resources/fact-sheet

George G, et al. Determining HIV risk for Adolescent Girls and Young Women (AGYW) in relationships with “Blessers” and age-disparate partners: a cross-sectional survey in four districts in South Africa. BMC Public Health. 2022;22(1):973. https://doi.org/10.1186/s12889-022-13394-4.CrossRefPubMedPubMedCentral

Kamire V, et al. HIV risk factors and risk perception among adolescent girls and young women: results from a population-based survey in Western Kenya, 2018. J Acquir Immune Defic Syndr. 2022;91(1):17–25. https://doi.org/10.1097/qai.0000000000003021.CrossRefPubMedPubMedCentral

J. B. Marrazzo, M,; Bekker LG, Celum, C.; Kiragu, M.; Leech, A.A.; Taylor, A.; Ussery, F.; Yang, J.; de Boer, M.; Carter, C.; Das, M.; Baeten,J.M.; Tao, L. 8+ years pooled analysis: Adherence and HIV incidence in >6000 women on F/TDF for PrEP. Oral presentation at the 30th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA, 2023: Abstract 163.

Tapsoba JD, et al. Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: results from a prospective cohort study. PLoS Med. 2022;19(9): e1004097. https://doi.org/10.1371/journal.pmed.1004097.CrossRefPubMedPubMedCentral

Were D, et al. Using a HIV prevention cascade for identifying missed opportunities in PrEP delivery in Kenya: results from a programmatic surveillance study. J Int AIDS Soc. 2020;23(3): e25537. https://doi.org/10.1002/jia2.25537.CrossRefPubMedPubMedCentral

Baeten JM, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410. https://doi.org/10.1056/NEJMoa1108524.CrossRefPubMedPubMedCentral

Baeten JM, et al. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. Lancet HIV. 2021;8(2):e87–95. https://doi.org/10.1016/s2352-3018(20)30304-0.CrossRefPubMedPubMedCentral

Heffron R, et al. Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa. Gates Open Res. 2017;1:3. https://doi.org/10.12688/gatesopenres.12752.2.CrossRefPubMed

10.

Thigpen MC, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34. https://doi.org/10.1056/NEJMoa1110711.CrossRefPubMed

11.

Nel A, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375(22):2133–43. https://doi.org/10.1056/NEJMoa1602046.CrossRefPubMed

12.

Fonner VA, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30(12):1973–83. https://doi.org/10.1097/qad.0000000000001145.CrossRefPubMed

13.

Celum C, et al. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: results from HPTN 082, a randomized controlled trial. PLoS Med. 2021;18(6): e1003670. https://doi.org/10.1371/journal.pmed.1003670.CrossRefPubMedPubMedCentral

14.

Celum CL, et al. PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project. J Int AIDS Soc. 2022;25(7): e25962. https://doi.org/10.1002/jia2.25962.CrossRefPubMedPubMedCentral

15.

Celum CL, et al. Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial. J Int AIDS Soc. 2020;23(11): e25636. https://doi.org/10.1002/jia2.25636.CrossRefPubMedPubMedCentral

16.

de Dieutapsoba J, et al. Persistence of oral pre-exposure prophylaxis (PrEP) among adolescent girls and young women initiating PrEP for HIV prevention in Kenya. AIDS Care. 2021;33(6):712–20. https://doi.org/10.1080/09540121.2020.1822505.CrossRef

17.

Haberer JE, et al. Effect of SMS reminders on PrEP adherence in young Kenyan women (MPYA study): a randomised controlled trial. Lancet HIV. 2021;8(3):e130–7. https://doi.org/10.1016/s2352-3018(20)30307-6.CrossRefPubMedPubMedCentral

18.

Irungu E, Khoza N, Velloza J. Multi-level interventions to promote oral pre-exposure prophylaxis use among adolescent girls and young women: a review of recent research. Curr HIV/AIDS Rep. 2021;18(6):490–9. https://doi.org/10.1007/s11904-021-00576-9.CrossRefPubMedPubMedCentral

19.

Baeten JM, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121–32. https://doi.org/10.1056/NEJMoa1506110.CrossRefPubMedPubMedCentral

20.

Nel A, et al. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study. Lancet HIV. 2021;8(2):e77–86. https://doi.org/10.1016/s2352-3018(20)30300-3.CrossRefPubMed

21.

Brown ER, et al. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial. J Int AIDS Soc. 2020;23(11): e25634. https://doi.org/10.1002/jia2.25634.CrossRefPubMedPubMedCentral

22.

Haberer JE, et al. Understanding pre-exposure prophylaxis adherence in young women in Kenya. J Acquir Immune Defic Syndr. 2022;89(3):251–60. https://doi.org/10.1097/qai.0000000000002876.CrossRefPubMed

23.

Haberer JE, Mujugira A, Mayer KH. The future of HIV pre-exposure prophylaxis adherence: reducing barriers and increasing opportunities. Lancet HIV. 2023. https://doi.org/10.1016/s2352-3018(23)00079-6.CrossRefPubMed

24.

Mayanja Y, et al. Oral pre-exposure prophylaxis preference, uptake, adherence and continuation among adolescent girls and young women in Kampala, Uganda: a prospective cohort study. J Int AIDS Soc. 2022;25(5): e25909. https://doi.org/10.1002/jia2.25909.CrossRefPubMedPubMedCentral

25.

Velloza J, et al. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study. J Int AIDS Soc. 2020;23(3): e25463. https://doi.org/10.1002/jia2.25463.CrossRefPubMedPubMedCentral

26.

Husnik MJ, et al. Correlates of adherence to the dapivirine vaginal ring for HIV-1 prevention. AIDS Behav. 2021;25(9):2801–14. https://doi.org/10.1007/s10461-021-03231-x.CrossRefPubMedPubMedCentral

27.

Nair G, et al. Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover tria. Lancet HIV. 2023. https://doi.org/10.1016/s2352-3018(23)00227-8.CrossRefPubMed

28.

Ngure K, et al. Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study). PLoS ONE. 2023;18(6): e0287525. https://doi.org/10.1371/journal.pone.0287525.CrossRefPubMedPubMedCentral

29.

Castillo-Mancilla JR, et al. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2013;29(2):384–90. https://doi.org/10.1089/aid.2012.0089.CrossRefPubMedPubMedCentral

30.

Baron EC, Davies T, Lund C. Validation of the 10-item centre for epidemiological studies depression scale (CES-D-10) in Zulu, Xhosa and Afrikaans populations in South Africa. BMC Psychiatry. 2017. https://doi.org/10.1186/s12888-016-1178-x.CrossRefPubMedPubMedCentral

31.

Johnson NA, et al. “Effect of electronic screening and brief intervention on hazardous or harmful drinking among adults in the hospital outpatient setting: a randomized, double-blind, controlled trial. Drug Alcohol Depend. 2018;191:78–85. https://doi.org/10.1016/j.drugalcdep.2018.06.030.CrossRefPubMed

32.

Bruwer B, Emsley R, Kidd M, Lochner C, Seedat S. Psychometric properties of the multidimensional scale of perceived social support in youth. Compr Psychiatry. 2008;49(2):195–201. https://doi.org/10.1016/j.comppsych.2007.09.002.CrossRefPubMed

33.

Morean ME, et al. Psychometrically improved, abbreviated versions of three classic measures of impulsivity and self-control. Psychol Assess. 2014;26(3):1003–20. https://doi.org/10.1037/pas0000003.CrossRefPubMedPubMedCentral

34.

Nakigudde J, Musisi S, Ehnvall A, Airaksinen E, Agren H. Adaptation of the multidimensional scale of perceived social support in a Ugandan setting. Afr Health Sci. 2009;9:35–41.

35.

Zimet GD, Dahlem NW, Zimet SG, Farley GK. The multidimensional scale of perceived social support. J Pers Assess. 1988;52(1):30–41. https://doi.org/10.1207/s15327752jpa5201_2.CrossRef

36.

B. A. F. Kenneth Ngure, Daniel W. Szydlo, Sarah T. Roberts, Morgan Garcia, Lisa Levy, Carolyne A. Akello, Krishnaveni Reddy, Thesla Palanee-Phillips, Pippa Macdonald, Bekezela Siziba, Lydia Soto-Torres, Sybil Hosek, Sharon L. Hillier, Gonasagrie Nair, Connie Celum, Ariane van der Straten., “Baseline Preferences for Oral Pre-exposure Prophylaxis (PrEP) or Dapivirine Intravaginal Ring for HIV Prevention among Adolescent Girls and Young Women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 Study) (In Press),” PLoS ONE.

37.

D. C. Division of AIDS Cross-Network Transgender Working Group Guidance on the Use of Gender-Inclusive HIV Research Practices: Protocol Design, and Data Reporting.March 2020. https://daidslearningportal.niaid.nih.gov/pluginfile.php/1/local_pages/pagecontent/Guidance%20on%20the%20Use%20of%20Gender-Inclusive%20HIV%20Research%20Practices.docx

38.

Maughan-Brown B, Evans M, George G. Sexual behaviour of men and women within age-disparate partnerships in South Africa: implications for Young Women’s HIV Risk. PLoS ONE. 2016;11(8): e0159162. https://doi.org/10.1371/journal.pone.0159162.CrossRefPubMedPubMedCentral

39.

Wamoyi J, Stobeanau K, Bobrova N, Abramsky T, Watts C. “Transactional sex and risk for HIV infection in sub-Saharan Africa: a systematic review and meta-analysis. J Int AIDS Soc. 2016;19(1):20992. https://doi.org/10.7448/ias.19.1.20992.CrossRefPubMedPubMedCentral

40.

Glick JL, et al. The PrEP care continuum among cisgender women who sell sex and/or use drugs globally: a systematic review. AIDS Behav. 2020;24(5):1312–33. https://doi.org/10.1007/s10461-019-02733-z.CrossRefPubMedPubMedCentral

41.

Joshi S, et al. PrEP uptake and persistence amongst HIV-negative women who exchange sex for money or commodities in Kampala, Uganda: a qualitative inquiry assessing the influence of pregnancy. PLOS Glob Public Health. 2023;3(6): e0000434. https://doi.org/10.1371/journal.pgph.0000434.CrossRefPubMedPubMedCentral

42.

Giovenco D, et al. Experiences of oral pre-exposure prophylaxis (PrEP) use disclosure among South African adolescent girls and young women and its perceived impact on adherence. PLoS ONE. 2021;16(3): e0248307. https://doi.org/10.1371/journal.pone.0248307.CrossRefPubMedPubMedCentral

43.

Katz AWK, et al. Qualitative analysis using social maps to explore young women’s experiences with social support of their oral PrEP use in Kenya and South Africa. J Assoc Nurses AIDS Care. 2023;34(1):45–57. https://doi.org/10.1097/jnc.0000000000000363.CrossRefPubMed

44.

Young AM, et al. Adolescent girls and young women’s experiences with disclosing Oral PrEP or dapivirine vaginal ring use: a multi-country qualitative analysis. AIDS Behav. 2023. https://doi.org/10.1007/s10461-023-04109-w.CrossRefPubMedPubMedCentral

45.

Ngure K, et al. Pills, injections, rings, or implants? PrEP formulation preferences of PrEP-experienced African women for HIV prevention. J Acquir Immune Defic Syndr. 2021;88(4):e30–2. https://doi.org/10.1097/qai.0000000000002793.CrossRefPubMedPubMedCentral

46.

Gichane MW, et al. Impact of women’s home environment on use of the dapivirine vaginal ring for HIV prevention in Sub-Saharan Africa. AIDS Behav. 2021;25(12):3847–57. https://doi.org/10.1007/s10461-021-03311-y.CrossRefPubMedPubMedCentral

47.

Rousseau E, et al. Adolescent girls and young women’s PrEP-user journey during an implementation science study in South Africa and Kenya. PLoS ONE. 2021;16(10): e0258542. https://doi.org/10.1371/journal.pone.0258542.CrossRefPubMedPubMedCentral

48.

Ortblad KF, Mogere P, Bukusi E, Ngure K, Baeten JM. Pharmacy delivery to expand the reach of PrEP in Africa. J Int AIDS Soc. 2020;23(9): e25619. https://doi.org/10.1002/jia2.25619.CrossRefPubMedPubMedCentral

49.

Lanham M, et al. Engaging male partners in women’s microbicide use: evidence from clinical trials and implications for future research and microbicide introduction. J Int AIDS Soc. 2014;17(3 Suppl 2):19159. https://doi.org/10.7448/ias.17.3.19159.CrossRefPubMedPubMedCentral

50.

Montgomery ET, et al. Male partner influence on women’s HIV prevention trial participation and use of pre-exposure prophylaxis: the importance of “understanding.” AIDS Behav. 2015;19(5):784–93. https://doi.org/10.1007/s10461-014-0950-5.CrossRefPubMedPubMedCentral

51.

Giovenco D, et al. The effect of PrEP use disclosure on adherence in a cohort of adolescent girls and young women in South Africa. AIDS Behav. 2022;26(4):1007–16. https://doi.org/10.1007/s10461-021-03455-x.CrossRefPubMed

52.

Roberts ST, Mancuso N, Williams K, Kalule HN, Mposula H, Mugocha C, Mvinjelwa P, Garcia M, Szydlo D, Soto-Torres L, Ngure K, Hosek S. Strategies to support effective use of the vaginal ring and oral PrEP among adolescent girls and young women in sub-Saharan Africa: Qualitative findings from MTN-034/REACH. J Int AIDS Soc. 2022;25:183–4.

Title: Correlates of Adherence to Oral and Vaginal Pre-exposure Prophylaxis (PrEP) Among Adolescent Girls and Young Women (AGYW) Participating in the MTN-034/REACH Trial
Authors: Kenneth Ngure
Erica N. Browne
Krishnaveni Reddy
Barbara A. Friedland
Ariane van der Straten
Thesla Palanee-Phillips
Rita Nakalega
Brenda Gati
Hadijah N. Kalule
Bekezela Siziba
Lydia Soto-Torres
Gonasagrie Nair
Morgan Garcia
Connie Celum
Sarah T. Roberts
Publication date: 09-06-2024
Publisher: Springer US
Keyword: Human Immunodeficiency Virus
Published in: AIDS and Behavior / Issue 9/2024
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-024-04382-3

“That’s My Girl; I love her”: The Promise of Compassionate, Inclusive Healthcare for Black Transgender Women to Support PrEP Use

Human Immunodeficiency Virus
Original Paper

Outcomes of Patients Living with HIV Hospitalized due to COVID-19: A 3-Year Nationwide Study (2020–2022)

Open Access
Human Immunodeficiency Virus
Original Paper

Is the Differentiated Service Delivery Model Suited to the Needs of People Living with HIV in Rwanda?

Human Immunodeficiency Virus
Original Paper

The Risks for HIV and Sexually Transmitted Infections Among Men Who Have Sex with Men Who Engage in Chemsex in Low- and Middle-Income Countries: A Mixed Methods Systematic Review and Meta-Analysis

Human Immunodeficiency Virus
Substantive Review

Examining the Effects of PrEP Use on Sexual Behaviors and Sexually Transmitted Infections Among Chinese Men who have Sex with Men: A Cross-Sectional Study

Open Access
Sexually Transmitted Infection
Original Paper

Correlates of Intimate Partner Violence, Including Psychological Partner Violence, in a Multisite U.S. Cohort of People in HIV Care

Human Immunodeficiency Virus
Original Paper

Women’s health knowledge hub

Menopause
Clinical Collection

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Live
Webinar | 27-05-2025 | 18:00 (CEST)

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Join this session to learn more about novel biomarkers for diagnosis and monitoring and familiarise yourself with current and emerging targeted therapies.

Join us live: Tuesday 27th May, 18:00-19:15 (CEST)

Prof. Edward Vital

Prof. Ronald F. van Vollenhoven

Developed by: Springer Medicine

Keynote series | Spotlight on managing health in obesity

Springer Medicine

Correlates of Adherence to Oral and Vaginal Pre-exposure Prophylaxis (PrEP) Among Adolescent Girls and Young Women (AGYW) Participating in the MTN-034/REACH Trial

Abstract

Other articles of this Issue 9/2024

“That’s My Girl; I love her”: The Promise of Compassionate, Inclusive Healthcare for Black Transgender Women to Support PrEP Use

Outcomes of Patients Living with HIV Hospitalized due to COVID-19: A 3-Year Nationwide Study (2020–2022)

Is the Differentiated Service Delivery Model Suited to the Needs of People Living with HIV in Rwanda?

The Risks for HIV and Sexually Transmitted Infections Among Men Who Have Sex with Men Who Engage in Chemsex in Low- and Middle-Income Countries: A Mixed Methods Systematic Review and Meta-Analysis

Examining the Effects of PrEP Use on Sexual Behaviors and Sexually Transmitted Infections Among Chinese Men who have Sex with Men: A Cross-Sectional Study

Correlates of Intimate Partner Violence, Including Psychological Partner Violence, in a Multisite U.S. Cohort of People in HIV Care

Women’s health knowledge hub

Keynote webinar | Spotlight on advances in lupus

Keynote series | Spotlight on managing health in obesity

Springer Medicine

Abstract

Please log in to get access to this content